Эпидемиологическая ситуация по папилломавирусной инфекции в США



  1. Weinstock H., Berman S., Cates W. Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004;36:6-10.
  2. Koutsky L.A., Kiviat N.B. Genital human papillomavirus. In: Holmes K.K., Sparling P.F., Mardh PA. et al, eds. Sexually transmitted diseases. New York, NY: McGraw-Hill; 1999:347-59.
  3. NIH Consensus Statement. Cervical cancer. NIH Consens Statement1996; 14:1-38.
  4. World Health Organization. IARC monograph on the evaluation of carcinogenic risks to humans: human papillomaviruses. 1995. Lyons, France, IARC; 2000.
  5. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl.J. Med. 2003;348:518-27.
  6. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol1999;189:12-9.
  7. Bosch F.X., de S.S.. Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13.
  8. World Health Organization. HPV IARC monograph summary. Lancet Oncology 2005;6:204.
  9. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
  10. Daling J.R., Weiss N.S., Klopfenstein L.L., Cochran L.E., Chow W.H., Daifuku R. Correlates of homosexual behavior and the incidence of analcancer. JAMA 1982;247:1988-90.
  11. Daling J.R., Weiss N.S., Hislop T.G. et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med1987;317:973-7.
  12. Holly E.A., Whittemore A.S., Aston D.A., Ahn D.K., Nickoloff B.J.,Kristiansen J.J. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 1989;81:1726-31.
  13. Koblin B.A., Hessol N.A., Zauber A.G. et al. Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978-1990.Am J Epidemiol 1996;144:916-23.
  14. Ries L., Kosery C., Hankey B., Miller B., Clegg L., Edwards B. SEER Cancer Statistics Review 1973-1996. Bethesda, MD: National Cancer Institute;1999.
  15. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-75.
  16. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur H.H. Classification of papillomaviruses. Virology 2004;324:17-27.
  17. Duensing S., Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004;109:157-62.
  18. Stanley M. Immune responses to human papillomavirus. Vaccine2006;24:S16-S22.
  19. Carter J.J., Koutsky L.A., Hughes J.P., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-9.
  20. Ho G.Y., Studentsov Y.Y., Bierman R., Burk R.D. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004;13:110-6.
  21. Carter J.J., Koutsky L.A., Wipf G.C., et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996;174:927-936.
  22. Winer R.L., Lee SK, Hughes J.P., Adam D.E., Kiviat N.B., Koutsky L.A.Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26.
  23. Ho G.Y., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med1998;338:423-8.
  24. Moscicki A.B., Hills N., Shiboski S. et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
  25. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
  26. Karlsson R., Jonsson M., Edlund K., et al. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. Sex Transm Dis 1995;22:119-27.
  27. Ley C., Bauer H.M., Reingold A, et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst.1991;83:997-1003.
  28. Peyton C.L., Gravitt P.E., Hunt W.C., et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis2001;183:1554-64.
  29. Manhart L.E., Holmes K.K., Koutsky L.A., et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis2006;33:502-8.
  30. Trottier H., Franco E.L. The epidemiology of genital human papillomavirus infection. Vaccine 2006;24:1-15.
  31. Fairley C.K., Gay N.J., Forbes A., Abramson M., Garland S.M. Hand-genital transmission of genital warts? An analysis of prevalence data. EpidemiolInfect 1995;115:169-76.
  32. Marrazzo J.M., Stine K., Koutsky L.A. Genital human papillomavirus infection in women who have sex with women: a review. Am J ObstetGynecol 2000;183:770-4.
  33. Sun X.W., Kuhn L., Ellerbrock T.V., Chiasson M.A., Bush T.J., Wright T.C.Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997;337:1343-9.
  34. Fairley C.K. Prevalence of HPV DNA in cervical specimens in women with renal transplants: a comparison with dialysis-dependent patients and patients with renal impairment. Nephrology, Dialysis, Transplantation1994;9:416-20.
  35. Watts D.H., Koutsky L.A., Holmes K.K., et al. Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am J Obstet Gynecol 1998;178:365-73.
  36. Geijersstam V., Eklund C., Wang Z., et al. A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. Int J Cancer1999;80:489-93.
  37. Abma J.C., Martinez G.M., Mosher W.D., Dawson B.S.. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002.Vital Health Stat 2004;24:1-48.
  38. Mosher W.D., Chandra A., Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data 2006;362:1-55.
  39. Eaton D.K., Kann L., Kinchen S., et al. Youth risk behavior surveillance - United States, 2005. In: Surveillance Summaries, June 9, 2006. MMWR 2006;55(No. SS-5).
  40. Franco E.L., Villa L.L., Sobrinho J.P., et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-23.
  41. Molano M., Van den B.A., Plummer M., et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003;158:486-94.
  42. Moscicki A.B., Shiboski S., Broering J., et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132:277-84.
  43. Ho G.Y., Burk R.D., Klein S., et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
  44. Hildesheim A., Schiffman M.H., Gravitt P.E., et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
  45. Schlecht N.F., Platt R.W., Duarte-Franco E., et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003;95:1336-43.
  46. Schiffman M., Kjaer S.K. Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003;31:14-9.
  47. Moscicki A.B., Schiffman M., Kjaer S., Villa L.L. Updating the natural history of HPV and anogenital cancer. Vaccine 2006;24:S42-S51.
  48. Wheeler C.M., Hunt W.C., Schiffman M., Castle PE. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis 2006;194:1291-9.
  49. Castellsague X., Munoz N. Cofactors in human papillomavirus carcinogenesis - role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003;31:20-8.
  50. Zelmanowicz A.M., Schiffman M., Herrero R., et al. Family history as a co-factor for adenocarcinoma and squamous cell carcinoma of the uterine cervix: results from two studies conducted in Costa Rica and the United States. Int J Cancer 2005;116:599-605.
  51. Munoz N., Castellsague X., de Gonzalez A.B., Gissmann L. HPV in the etiology of human cancer. Vaccine 2006;24:S1-S10.
  52. Revzina N.V., Diclemente R.J. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS 2005;16:528-37.
  53. Burk R.D., Kelly P., Feldman J., et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996;23:333-41.
  54. Wheeler C.M., Parmenter C.A., Hunt W.C., et al. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sex Transm Dis 1993;20:286-9.
  55. Datta D.S., Koutsky L., Douglas J.M., et al. Sentinel surveillance for human papillomavirus among women in the United States, 2003--2004 [Abstract MO-306 ISSTDR]. Amsterdam; 2005-2006.
  56. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the US; National health and nutrition examination survey (NHANES), 2003-2004. JAMA 2007;297:813-9.
  57. Stone K.M., Karem K.L., Sternberg M.R., et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis2002;186:1396-402.
  58. Baldwin S.B., Wallace D.R., Papenfuss M.R., et al. Human papillomavirus infection in men attending a sexually transmitted disease clinic. J Infect Dis 2003;187:1064-70.
  59. Hernandez B.Y., McDuffie K., Goodman M.T., et al. Comparison of physician- and self-collected genital specimens for detection of human papillomavirus in men. J Clin Microbiol 2006;44:513-7.
  60. Weaver B.A., Feng Q., Holmes K.K., et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis 2004; 189:677-85.
  61. Partridge J.M., Koutsky L.A. Genital human papillomavirus infection in men. Lancet Infect Dis 2006;6:21-31.
  62. Dunne E.F., Nielson C.M., Stone K.M., Markowitz L.E., Giuliano A.R. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006;194:1044-57.
  63. Saslow D., Runowicz C.D., Solomon D., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62.
  64. Schiffman M., Brinton L., Devesa S., Fraumeni J. Cervical cancer. In: Schottenfeld D, Fraumeni J, eds. Cancer epidemiology and prevention. New York, NY: Oxford University Press; 1996:1090-128.
  65. Smith H.O., Tiffany M.F., Qualls C.R., Key C.R. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year population-based study. Gynecol Oncol 2000;78:97-105.
  66. Hildesheim A., Berrington de G.A. Etiology and prevention of cervical adenocarcinomas. J Natl Cancer Inst 2006;98:292-3.
  67. Saraiya M., Ahmed F., Krishnan S., Richards T., Unger E., Lawson H.W. Cervical cancer incidence in a prevaccine era in the United States, 19982002. Obstet Gynecol 2007;109:360-70.
  68. US Cancer Statistics Working Group. United States cancer statistics: 2003. Incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC and the National Cancer Institute. 2005. Available at http://www.cdc.gov/uscs.
  69. Judson P.L., Habermann E.B., Baxter N.N., Durham S.B., Virnig B.A. Trends in the Incidence of Invasive and In Situ Vulvar Carcinoma. Obstet Gynecol 2006;107:1018-22.
  70. Johnson L.G., Madeleine M.M., Newcomer L.M., Schwartz S.M., Daling J.R. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973--2000. Cancer2004;101:281-8.
  71. Schottenfeld D., Winawer S. Cancers of the large intestine. In: Schottenfeld D, Fraumeni J, eds. Cancer epidemiology and prevention. New York, NY: Oxford University Press; 1996:813-40.
  72. Greer C.E., Wheeler C.M., Ladner M.B., et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995;33:2058-63.
  73. Winer R.L., Kiviat N.B., Hughes J.P., et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis2005;191:731-8.
  74. Chuang T.Y., Perry H.O., Kurland L.T., Ilstrup D.M. Condyloma acuminatum in Rochester, Minn., 1950-1978. I. Epidemiology and clinical features.Arch Dermatol 1984;120:469-75.
  75. Insinga R.P., Dasbach E.J., Myers E.R. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003;36:1397-403.
  76. Reeves W.C., Ruparelia S.S., Swanson K.I., Derkay C.S., Marcus A., Unger ER. National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003;129:976-82.
  77. Armstrong L.R., Preston E.J., Reichert M., et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis 2000;31:107-9.
  78. CDC. Sexually transmitted diseases treatment guidelines, 2002. MMWR2002;51(No. RR-6).
  79. Winer R.L., Hughes J.P., Feng Q., et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J.